Ten-year survival in patients with metastatic prostate cancer

Catherine M. Tangen, James R. Faulkner, E. David Crawford, Ian M. Thompson, Daisaku Hirano, Mario Eisenberger, Maha Hussain

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The objective of this analysis is to identify baseline covariates that predict which patients will be long-term survivors with metastatic prostate cancer. We analyzed data from Southwest Oncology Group (SWOG) S8894, a clinical trial in men with newly diagnosed metastatic prostate cancer, to evaluate pretreatment characteristics associated with 10-year survival. There were 1286 eligible patients randomized to this study. Of these, 794 have been followed for ≥ 10.5 years and are included in the analyses. Proportional odds models were used to predict 3 survival categories (survival for < 5 years, 5 up to 10 years, and ≥ 10 years). Baseline patient and disease characteristics investigated were protocol treatment (flutamide vs. placebo), severity of disease, SWOG performance status (PS), bone pain, Gleason score, race, age, and prostate-specific antigen (PSA) level at study entry. Of the 794 evaluable patients, 77% lived < 5 years, 16% lived 5 up to 10 years, and 7% lived ≥ 10 years. Factors predicting a statistical significant association with longer survival (P < 0.05) included minimal disease, better PS, no bone pain, lower Gleason score, and lower PSA level. All but PS were also significant in multivariate analyses. However, only 13% of patients (5 of 38) who lived ≥ 10 years were correctly predicted in their survival category based on the model, whereas 98% (405 of 414) who died within the first 5 years were correctly predicted. Although statistically significant baseline characteristics were identified in this clinical trial, they did not accurately predict the survival interval to which a patient belonged.

Original languageEnglish (US)
Pages (from-to)41-45
Number of pages5
JournalClinical Prostate Cancer
Volume2
Issue number1
StatePublished - Jun 2003

Fingerprint

Prostatic Neoplasms
Survival
Neoplasm Grading
Prostate-Specific Antigen
Clinical Trials
Flutamide
Bone and Bones
Pain
Clinical Protocols
Survivors
Multivariate Analysis
Placebos

Keywords

  • Flutamide
  • Gleason score
  • Long-term survival
  • Multivariable analysis
  • Orchiectomy
  • Prediction
  • Prognosis
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Tangen, C. M., Faulkner, J. R., Crawford, E. D., Thompson, I. M., Hirano, D., Eisenberger, M., & Hussain, M. (2003). Ten-year survival in patients with metastatic prostate cancer. Clinical Prostate Cancer, 2(1), 41-45.

Ten-year survival in patients with metastatic prostate cancer. / Tangen, Catherine M.; Faulkner, James R.; Crawford, E. David; Thompson, Ian M.; Hirano, Daisaku; Eisenberger, Mario; Hussain, Maha.

In: Clinical Prostate Cancer, Vol. 2, No. 1, 06.2003, p. 41-45.

Research output: Contribution to journalArticle

Tangen, CM, Faulkner, JR, Crawford, ED, Thompson, IM, Hirano, D, Eisenberger, M & Hussain, M 2003, 'Ten-year survival in patients with metastatic prostate cancer', Clinical Prostate Cancer, vol. 2, no. 1, pp. 41-45.
Tangen CM, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M et al. Ten-year survival in patients with metastatic prostate cancer. Clinical Prostate Cancer. 2003 Jun;2(1):41-45.
Tangen, Catherine M. ; Faulkner, James R. ; Crawford, E. David ; Thompson, Ian M. ; Hirano, Daisaku ; Eisenberger, Mario ; Hussain, Maha. / Ten-year survival in patients with metastatic prostate cancer. In: Clinical Prostate Cancer. 2003 ; Vol. 2, No. 1. pp. 41-45.
@article{b85f09e6b96543008d7607c3d2e5777f,
title = "Ten-year survival in patients with metastatic prostate cancer",
abstract = "The objective of this analysis is to identify baseline covariates that predict which patients will be long-term survivors with metastatic prostate cancer. We analyzed data from Southwest Oncology Group (SWOG) S8894, a clinical trial in men with newly diagnosed metastatic prostate cancer, to evaluate pretreatment characteristics associated with 10-year survival. There were 1286 eligible patients randomized to this study. Of these, 794 have been followed for ≥ 10.5 years and are included in the analyses. Proportional odds models were used to predict 3 survival categories (survival for < 5 years, 5 up to 10 years, and ≥ 10 years). Baseline patient and disease characteristics investigated were protocol treatment (flutamide vs. placebo), severity of disease, SWOG performance status (PS), bone pain, Gleason score, race, age, and prostate-specific antigen (PSA) level at study entry. Of the 794 evaluable patients, 77{\%} lived < 5 years, 16{\%} lived 5 up to 10 years, and 7{\%} lived ≥ 10 years. Factors predicting a statistical significant association with longer survival (P < 0.05) included minimal disease, better PS, no bone pain, lower Gleason score, and lower PSA level. All but PS were also significant in multivariate analyses. However, only 13{\%} of patients (5 of 38) who lived ≥ 10 years were correctly predicted in their survival category based on the model, whereas 98{\%} (405 of 414) who died within the first 5 years were correctly predicted. Although statistically significant baseline characteristics were identified in this clinical trial, they did not accurately predict the survival interval to which a patient belonged.",
keywords = "Flutamide, Gleason score, Long-term survival, Multivariable analysis, Orchiectomy, Prediction, Prognosis, Prostate-specific antigen",
author = "Tangen, {Catherine M.} and Faulkner, {James R.} and Crawford, {E. David} and Thompson, {Ian M.} and Daisaku Hirano and Mario Eisenberger and Maha Hussain",
year = "2003",
month = "6",
language = "English (US)",
volume = "2",
pages = "41--45",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Ten-year survival in patients with metastatic prostate cancer

AU - Tangen, Catherine M.

AU - Faulkner, James R.

AU - Crawford, E. David

AU - Thompson, Ian M.

AU - Hirano, Daisaku

AU - Eisenberger, Mario

AU - Hussain, Maha

PY - 2003/6

Y1 - 2003/6

N2 - The objective of this analysis is to identify baseline covariates that predict which patients will be long-term survivors with metastatic prostate cancer. We analyzed data from Southwest Oncology Group (SWOG) S8894, a clinical trial in men with newly diagnosed metastatic prostate cancer, to evaluate pretreatment characteristics associated with 10-year survival. There were 1286 eligible patients randomized to this study. Of these, 794 have been followed for ≥ 10.5 years and are included in the analyses. Proportional odds models were used to predict 3 survival categories (survival for < 5 years, 5 up to 10 years, and ≥ 10 years). Baseline patient and disease characteristics investigated were protocol treatment (flutamide vs. placebo), severity of disease, SWOG performance status (PS), bone pain, Gleason score, race, age, and prostate-specific antigen (PSA) level at study entry. Of the 794 evaluable patients, 77% lived < 5 years, 16% lived 5 up to 10 years, and 7% lived ≥ 10 years. Factors predicting a statistical significant association with longer survival (P < 0.05) included minimal disease, better PS, no bone pain, lower Gleason score, and lower PSA level. All but PS were also significant in multivariate analyses. However, only 13% of patients (5 of 38) who lived ≥ 10 years were correctly predicted in their survival category based on the model, whereas 98% (405 of 414) who died within the first 5 years were correctly predicted. Although statistically significant baseline characteristics were identified in this clinical trial, they did not accurately predict the survival interval to which a patient belonged.

AB - The objective of this analysis is to identify baseline covariates that predict which patients will be long-term survivors with metastatic prostate cancer. We analyzed data from Southwest Oncology Group (SWOG) S8894, a clinical trial in men with newly diagnosed metastatic prostate cancer, to evaluate pretreatment characteristics associated with 10-year survival. There were 1286 eligible patients randomized to this study. Of these, 794 have been followed for ≥ 10.5 years and are included in the analyses. Proportional odds models were used to predict 3 survival categories (survival for < 5 years, 5 up to 10 years, and ≥ 10 years). Baseline patient and disease characteristics investigated were protocol treatment (flutamide vs. placebo), severity of disease, SWOG performance status (PS), bone pain, Gleason score, race, age, and prostate-specific antigen (PSA) level at study entry. Of the 794 evaluable patients, 77% lived < 5 years, 16% lived 5 up to 10 years, and 7% lived ≥ 10 years. Factors predicting a statistical significant association with longer survival (P < 0.05) included minimal disease, better PS, no bone pain, lower Gleason score, and lower PSA level. All but PS were also significant in multivariate analyses. However, only 13% of patients (5 of 38) who lived ≥ 10 years were correctly predicted in their survival category based on the model, whereas 98% (405 of 414) who died within the first 5 years were correctly predicted. Although statistically significant baseline characteristics were identified in this clinical trial, they did not accurately predict the survival interval to which a patient belonged.

KW - Flutamide

KW - Gleason score

KW - Long-term survival

KW - Multivariable analysis

KW - Orchiectomy

KW - Prediction

KW - Prognosis

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=0041977276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041977276&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 41

EP - 45

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 1

ER -